Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Ai Takemoto"'
Autor:
Mai Suzuki, Ken Uchibori, Tomoko Oh-hara, Yumi Nomura, Ryusei Suzuki, Ai Takemoto, Mitsugu Araki, Shigeyuki Matsumoto, Yukari Sagae, Mutsuko Kukimoto-Niino, Yusuke Kawase, Mikako Shirouzu, Yasushi Okuno, Makoto Nishio, Naoya Fujita, Ryohei Katayama
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-13 (2024)
Abstract Brigatinib-based therapy was effective against osimertinib-resistant EGFR C797S mutants and is undergoing clinical studies. However, tumor relapse suggests additional resistance mutations might emerge. Here, we first demonstrated the binding
Externí odkaz:
https://doaj.org/article/b24524fa05214c18b25d982517bfb2eb
Autor:
Hayato Mizuta, Koutaroh Okada, Mitsugu Araki, Jun Adachi, Ai Takemoto, Justyna Kutkowska, Kohei Maruyama, Noriko Yanagitani, Tomoko Oh-hara, Kana Watanabe, Keiichi Tamai, Luc Friboulet, Kazuhiro Katayama, Biao Ma, Yoko Sasakura, Yukari Sagae, Mutsuko Kukimoto-Niino, Mikako Shirouzu, Satoshi Takagi, Siro Simizu, Makoto Nishio, Yasushi Okuno, Naoya Fujita, Ryohei Katayama
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-16 (2021)
Resistance to ALK inhibitors such as lorlatinib often arise due to on-target mutations. Here, the authors show the multi-kinase inhibitor gilteritinib is effective against different mutations that arise during lorlatinib in ALK fusion positive lung c
Externí odkaz:
https://doaj.org/article/57a69b4d14e444839652b6a01ced7b32
Autor:
Ray Sagawa, Seiji Sakata, Bo Gong, Yosuke Seto, Ai Takemoto, Satoshi Takagi, Hironori Ninomiya, Noriko Yanagitani, Masayuki Nakao, Mingyon Mun, Ken Uchibori, Makoto Nishio, Yasunari Miyazaki, Yuichi Shiraishi, Seishi Ogawa, Keisuke Kataoka, Naoya Fujita, Kengo Takeuchi, Ryohei Katayama
Publikováno v:
JCI Insight, Vol 7, Iss 1 (2022)
Immune checkpoint therapy targeting the PD-1/PD-L1 axis is a potentially novel development in anticancer therapy and has been applied to clinical medicine. However, there are still some problems, including a relatively low response rate, innate mecha
Externí odkaz:
https://doaj.org/article/1739d19c47714e029cf1f8d55b3d0650
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-12 (2017)
Abstract Podoplanin/Aggrus, known as a platelet aggregation-inducing factor, is frequently overexpressed in lung squamous cell carcinomas (LSCC) and glioblastomas among other tumours, and its expression has been reported to be correlated with poor pr
Externí odkaz:
https://doaj.org/article/0c32808f24e244388c9c730032f18191
Autor:
Naoya Fujita, Ryohei Katayama, Tetsuo Noda, Kengo Takeuchi, Yoshiya Sugiura, Seiichi Matsumoto, Keisuke Ae, Yuki Funauchi, Kenji Ichihara, Kazue Tsuji-Takayama, Minoru Sugawara, Tokuichi Kawaguchi, Marie Lebel, Asami Kobayashi, Miho Takami, Mamoru Kakino, Nobuhiko Gyobu, Takao Ukaji, Satoshi Takagi, Ai Takemoto
Purpose:Osteosarcoma, the most common bone malignancy in children, has a poor prognosis, especially when the tumor metastasizes to the lungs. Therefore, novel therapeutic strategies targeting both proliferation and metastasis of osteosarcoma are requ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4c9bc456f1478a6e9c52bc2b7a60df3
https://doi.org/10.1158/1078-0432.c.6532485
https://doi.org/10.1158/1078-0432.c.6532485
Autor:
Naoya Fujita, Ryohei Katayama, Tetsuo Noda, Kengo Takeuchi, Yoshiya Sugiura, Seiichi Matsumoto, Keisuke Ae, Yuki Funauchi, Kenji Ichihara, Kazue Tsuji-Takayama, Minoru Sugawara, Tokuichi Kawaguchi, Marie Lebel, Asami Kobayashi, Miho Takami, Mamoru Kakino, Nobuhiko Gyobu, Takao Ukaji, Satoshi Takagi, Ai Takemoto
Supplementary Data from Targeting Podoplanin for the Treatment of Osteosarcoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04d38f44848e5312442704a7c2827942
https://doi.org/10.1158/1078-0432.22487280
https://doi.org/10.1158/1078-0432.22487280
Autor:
Naoya Fujita, Ryohei Katayama, Tetsuo Noda, Kengo Takeuchi, Yoshiya Sugiura, Seiichi Matsumoto, Keisuke Ae, Yuki Funauchi, Kenji Ichihara, Kazue Tsuji-Takayama, Minoru Sugawara, Tokuichi Kawaguchi, Marie Lebel, Asami Kobayashi, Miho Takami, Mamoru Kakino, Nobuhiko Gyobu, Takao Ukaji, Satoshi Takagi, Ai Takemoto
Supplementary Figure from Targeting Podoplanin for the Treatment of Osteosarcoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::050e108ef8c5e298b42e83cdfa017e6a
https://doi.org/10.1158/1078-0432.22487277
https://doi.org/10.1158/1078-0432.22487277
Autor:
Ai Takemoto, Satoshi Takagi, Takao Ukaji, Nobuhiko Gyobu, Mamoru Kakino, Miho Takami, Asami Kobayashi, Marie Lebel, Tokuichi Kawaguchi, Minoru Sugawara, Kazue Tsuji-Takayama, Kenji Ichihara, Yuki Funauchi, Keisuke Ae, Seiichi Matsumoto, Yoshiya Sugiura, Kengo Takeuchi, Tetsuo Noda, Ryohei Katayama, Naoya Fujita
Publikováno v:
Clinical Cancer Research. 28:2633-2645
Purpose: Osteosarcoma, the most common bone malignancy in children, has a poor prognosis, especially when the tumor metastasizes to the lungs. Therefore, novel therapeutic strategies targeting both proliferation and metastasis of osteosarcoma are req
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44ba7ae5e92a36ebce7a64453a3bfb41
https://doi.org/10.1158/1078-0432.ccr-21-4509
https://doi.org/10.1158/1078-0432.ccr-21-4509
Autor:
Minoru Sugawara, Ryohei Katayama, Yuki Sasaki, Keisuke Ae, Ai Takemoto, Yosuke Seto, Sumie Koike, Masanori Saito, Yuki Funauchi, Seiichi Matsumoto, Naoya Fujita, Takao Ukaji, Satoshi Takagi, Mizuki Haraguchi, Tokuichi Kawaguchi
Publikováno v:
Oncogene
Osteosarcoma is the most common primary malignant bone cancer, with high rates of pulmonary metastasis. Osteosarcoma patients with pulmonary metastasis have worse prognosis than those with localized disease, leading to dramatically reduced survival r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4e65d68633869002042a92d80620083
https://doi.org/10.1038/s41388-021-01956-6
https://doi.org/10.1038/s41388-021-01956-6
Autor:
Ryohei Katayama, Mamoru Kakino, Takao Ukaji, Ai Takemoto, Satoshi Takagi, Harumi Shibata, Naoya Fujita
Publikováno v:
Cancer Science
Podoplanin is a key molecule for enhancing tumor‐induced platelet aggregation. Podoplanin interacts with CLEC‐2 on platelets via PLatelet Aggregation–inducing domains (PLAGs). Among our generated antibodies, those targeting the fourth PLAG doma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8055ba8436964955dabbc2476016e9e
https://doi.org/10.1111/cas.14891
https://doi.org/10.1111/cas.14891